Balchem Corporation Q2 2025 Financial Results

SEC Filing 8-K (0000009326-25-000012)

Balchem Corporation reported its financial results for the second quarter of 2025, ending June 30, 2025. The company achieved record net sales of $255.5 million, a 9.1% increase compared to the prior year quarter. Net earnings were $38.3 million, up 19.4% from the previous year. Adjusted EBITDA reached $69.2 million, an 11.2% increase, and free cash flow was $40.7 million. The Human Nutrition and Health segment saw record sales of $160.8 million, while the Animal Nutrition and Health segment reported sales of $56.0 million, a 13.1% increase. The Specialty Products segment also achieved record sales of $37.2 million. The company announced plans to build a new $36 million manufacturing facility in Orange County, NY, pending approval. Additionally, the European Commission imposed provisional anti-dumping duties on choline chloride imports from China, which is expected to benefit Balchem's competitive position.